Elafibranor not checked
Ipsen · GFT505 · IPN60190
FollowEvery change as it happens, and a Monday email
Trials
5 active
9 in total · 5 in the EU
What this is
- How it works
- Peroxisome Proliferator-activated Receptor Agonist FDA class
- How it’s given
- “Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily”In the company’s words, NCT06016842 on ClinicalTrials.gov
- Tested for
- Primary Sclerosing Cholangitis (2 trials), Primary Biliary Cirrhosis, Primary Biliary Cholangitis, Primary Biliary Cholangitis (PBC)
- Main trialPhase 3
- “The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and…”In the company’s words, NCT04526665 on ClinicalTrials.gov
- Other names
- GFT505 · IPN60190 · Iqirvo
Other drugs for Primary Sclerosing Cholangitis
- Norucholic acidDr. Falk Pharma GmbH · Phase 3
- MaralixibatMirum Pharmaceuticals, Inc. · Phase 3
- LB-P8LISCure Biosciences · Phase 2
- HK-660SCuromeBiosciences · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
- TAK-781Takeda · Phase 1
Coming up4
- 17 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 May 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Apr 2031Phase 3 trial completes · ClinicalTrials.gov
- 23 Sep 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Jun 2023 | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | |
| Phase 3Active, not recruiting | 17 Dec 2026 | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | |
| Phase 3Recruiting | 31 May 2029 | A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | |
| Phase 3Recruiting | 30 Apr 2031 | A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | |
| Phase 2Active, not recruiting | 23 Sep 2031 | A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. | |
| Phase 3Completed | 16 Jun 2026 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. | |
| Phase 2Completed | Feb 2015 | Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) | |
| Phase 1Completed | 30 Dec 2022 | A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet | |
| Phase 1Completed | 10 Mar 2023 | Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026